

**AMENDMENTS TO THE CLAIMS**

Claims 1-4 (Canceled)

5. (Previously presented) A non transgenic mouse mammary adenocarcinoma cell line, wherein the cell line is selected from the group consisting of MC4-L1 (ATCC# PTA-889), MC4-L3 (ATCC# PTA-891), MC4-L2 (ATCC# PTA-892) and MC7-L1 (ATCC # PTA-890).

Claims 6-10 (Canceled)

11. (Currently amended) A kit for ~~determining the effect of a hormone, anti-hormone, pharmacological compounds and environmental agents~~ evaluating the proliferation of cells, wherein the kit comprises an aliquot of a cell line selected from the group consisting of MC4-L1 (ATCC# PTA-889), MC4-L3 (ATCC# PTA-891), MC4-L2 (ATCC# PTA-892) and MC7-L1 (ATCC # PTA-890) and a method for evaluating the proliferation of cells.

12. (Canceled)

**SUMMARY OF TELEPHONIC INTERVIEW**

On April 6, 2004, the representative for the Applicants, Melissa W. Acosta, conducted a telephonic interview with the Examiner. The purpose of the telephonic interview was to query as to the reason that the Examiner withdrew the previous indication that claim 11 was allowable. The applicants and the Examiner discussed possible amendments to claim 11. One such amendment that was discussed is presented herein. The Examiner indicated that this amendment to claim 11 would obviate the pending rejection and the claim would be allowable.